<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-695X</journal-id>
<journal-title><![CDATA[Revista Clínica de Medicina de Familia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Clin Med Fam]]></abbrev-journal-title>
<issn>1699-695X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Medicina de Familia y Comunitaria]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-695X2018000100028</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento con antraciclinas, un antecedente sospechoso]]></article-title>
<article-title xml:lang="en"><![CDATA[Treatment with anthracyclines, a dubious precedent]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero-Barzola]]></surname>
<given-names><![CDATA[M. Yamina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sierra-Santos]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Salud Barrio del Pilar  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Salud de Manzanares el Real Consultorio de El Boalo ]]></institution>
<addr-line><![CDATA[El Boalo Madrid]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Sociedad Española de Medicina Familiar y Comunitaria Grupo de Trabajo de Genética y Enfermedades Raras ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2018</year>
</pub-date>
<volume>11</volume>
<numero>1</numero>
<fpage>28</fpage>
<lpage>30</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-695X2018000100028&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-695X2018000100028&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-695X2018000100028&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Presentamos el caso de una mujer de 72 años con antecedente de linfoma de Hodgkin B difuso hace 5 años, tratado con antraciclinas, con remisión completa del cuadro, a la que se le realizó ecocardiogramas de control durante 2 años, sin observarse alteración cardiaca. Consulta por disnea y nicturia. Ante el cuadro que refería y el antecedente del uso de antraciclinas se deriva al Servicio de Cardiología, donde se le realizaron pruebas que objetivaron miocardiopatía dilatada con marcada disminución de la fracción de eyección. Llamamos la atención sobre los efectos secundarios tardíos de este quimioterápico que, debido a la mayor supervivencia del cáncer, vamos a observar con mayor frecuencia cada vez, por lo que los médicos de familia deben conocer y sospecharlos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: We present the case of a 72-year-old woman with a history of diffuse Hodgkin&#8217;s lymphoma 5 years ago, treated with anthracyclines with complete remission of the disease, who underwent control echocardiograms during 2 years without any cardiac abnormalities. She consults for dyspnea and nocturia. In view of these symptoms and the history of anthracycline use, she was referred to the cardiology department where tests showed dilated cardiomyopathy with markedly decreased ejection fraction. Attention should be drawn to the late side effects of this chemotherapy which, due to increased survival of cancer patients, will appear more frequently and should therefore be known and suspected by general practitioners.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cardiotoxicidad]]></kwd>
<kwd lng="es"><![CDATA[Antraciclinas]]></kwd>
<kwd lng="es"><![CDATA[Quimioterapia]]></kwd>
<kwd lng="en"><![CDATA[Cardiotoxicity]]></kwd>
<kwd lng="en"><![CDATA[Anthracyclines]]></kwd>
<kwd lng="en"><![CDATA[Chemotherapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Agustí]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Tornos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicidad tardía inducida por antraciclinas]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2009</year>
<volume>133</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>311-3</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Damiani]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Moura]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Viau]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Caceres]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Henriques]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Saffi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone]]></article-title>
<source><![CDATA[Arch Toxicol]]></source>
<year>2016</year>
<volume>90</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2063-76</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Von Hoff]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Layard]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Basa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Davis Jr]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Von Hoff]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Rozencweig]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for doxorubicin-induced congestive heart failure]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1979</year>
<volume>91</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>710-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plana]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La quimioterapia y el corazón]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2011</year>
<volume>64</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>409-15</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fridrik]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Jaeger]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Petzer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Willenbacher]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Keil]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-MI study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT] (NHL-14)]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2016</year>
<volume>58</volume>
<page-range>112-21</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vicente-Hernández]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sarre-Álvarez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Weber]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Greene]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicidad por antraciclicos]]></article-title>
<source><![CDATA[Med Int Méx]]></source>
<year>2015</year>
<volume>31</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>567-77</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindsey]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Parsons]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aune]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure]]></article-title>
<source><![CDATA[Am J Physiol Heart Circ Physiol]]></source>
<year>2014</year>
<volume>307</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>H1379-89</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shahzad]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Ishtiaq]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zahid]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Anwer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors]]></article-title>
<source><![CDATA[BMJ Case Rep]]></source>
<year>2016</year>
<volume>2016</volume>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruggiero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ridola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Puma]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Molinari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Coccia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[De Rosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anthracycline cardiotoxicity in childhood]]></article-title>
<source><![CDATA[Pediatr Hematol Oncol]]></source>
<year>2008</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>261-81</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christiansen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Autschbach]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Doxorubicin in experimental and clinical heart failure]]></article-title>
<source><![CDATA[Eur J Cardiothorac Surg]]></source>
<year>2006</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>611-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
